Introduction: Guidelines recommend screening stroke-survivors for cognitive impairment. We sought to collate published data on test accuracy of stroke cognitive screening tools. Method: Index test was any direct, cognitive screening assessment and was compared against reference standard of any diagnosis of multi-domain cognitive impairment informed by clinical assessment/detailed neuropsychological battery. Using a sensitive search statement (relating to concepts of stroke, dementia, cognitive testing), we searched multiple, crossdisciplinary databases from inception to January 2014. We described risk of bias and generalisability using QUADAS2. Where data allowed, we pooled test accuracy metrics. Results: From 19,182 titles, we reviewed 241 papers; 35 were suitable for inclusion. There was substantial heterogeneity: 25 differing screening tests; stroke settings (acute stroke: n = 11 papers) and reference standards employed (neuropsychological battery: n = 21 papers). Only 1 paper was graded "low risk" for all QUADAS2 domains. We pooled data for 4 tests at various screen positive thresholds: ACE-R (<88/100) sensitivity: 0.96, specificity: 0.70 (2 studies); MMSE (<27/30) sensitivity: 0.71, specificity: 0.85 (12 studies); MoCA (<26/30) sensitivity: 0.95, specificity: 0.45 (4 studies); MoCA<22/30 sensitivity: 0.84, specificity: 0.78 (6 studies). R-CAMCOG (<33/49) sensitivity: 0.57, specificity: 0.92 (2 studies). Discussion: Common cognitive screening tools have similar test accuracy with no clear superior test. Choice should be informed by factors such as feasibility, acceptability and opportunity cost. For detection of dementia/ multi-domain cognitive impairment, MoCA used at "usual" threshold has high sensitivity but at the cost of specificity, properties may be more suitable when thresholds are adjusted. All results must be interpreted in the context of the modest numbers of included studies and substantial potential for bias.
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